Investor Relations

Epitomee develops paradigm-shifting ingestible therapeutic devices & platforms that deploy targeted therapies along the GI tract. We create clinically validated, safe ingestible treatments intended to manage metabolic diseases, obesity, and deliver biologics. The company went public following successful pivotal trials demonstrating significant clinical efficacy.

Epitomee has built an advanced suite of novel, targeted deployments combining mechanical, ingestible morphology platforms, and therapeutic agents. Limited side effects, specific localization, and maximum adherence.